Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Final report of RTOG 9610, a multi-institutional trial of reirradiation and chemotherapy for unresectable recurrent squamous cell carcinoma of the head and neck.

Spencer SA, Harris J, Wheeler RH, Machtay M, Schultz C, Spanos W, Rotman M, Meredith R, Ang KK.

Head Neck. 2008 Mar;30(3):281-8.

PMID:
17764087
2.

The long-term results of a pilot study of three times a day radiotherapy and escalating doses of daily cisplatin for locally advanced non-small-cell lung cancer.

Schild SE, Wong WW, Vora SA, Halyard MY, Northfelt DW, Kogut HL, Wheeler RH.

Int J Radiat Oncol Biol Phys. 2005 Aug 1;62(5):1432-7.

PMID:
16029804
3.

Head and neck cancers.

Forastiere AA, Ang K, Brizel D, Brockstein BE, Dunphy F, Eisele DW, Goepfert H, Hicks WL Jr, Kies MS, Lydiatt WM, Maghami E, McCaffrey T, Mittal BB, Pfister DG, Pinto HA, Posner MR, Ridge JA, Samant S, Schuller DE, Shah JP, Spencer S, Trotti A 3rd, Wheeler RH 3rd, Wolf GT, Worden F, Yueh B; National Comprehensive Cancer Network.

J Natl Compr Canc Netw. 2005 May;3(3):316-91. No abstract available.

PMID:
16002004
4.

Thinking of critical words during study is unnecessary for false memory in the Deese, Roediger, and McDermott procedure.

Seamon JG, Lee IA, Toner SK, Wheeler RH, Goodkind MS, Birch AD.

Psychol Sci. 2002 Nov;13(6):526-31.

PMID:
12430836
5.

Phase I study of hyperfractionated accelerated radiotherapy and escalating doses of daily cisplatin for patients with locally advanced non-small-cell lung cancer.

Schild SE, Wong WW, Vora SA, Halyard MY, Wheeler RH.

Int J Radiat Oncol Biol Phys. 2002 Nov 1;54(3):729-34.

PMID:
12377324
6.

Concurrent chemoradiation therapy with cisplatin and paclitaxel for locally advanced non-small cell lung cancer: long-term follow-up of a phase I trial.

Robert F, Spencer SA, Childs HA 3rd, Zhang R, Meredith RF, Wheeler RH, Hawkins MH, Carey D.

Lung Cancer. 2002 Aug;37(2):189-99.

PMID:
12140142
7.

RTOG 96-10: reirradiation with concurrent hydroxyurea and 5-fluorouracil in patients with squamous cell cancer of the head and neck.

Spencer SA, Harris J, Wheeler RH, Machtay M, Schultz C, Spanos W, Rotman M, Meredith R.

Int J Radiat Oncol Biol Phys. 2001 Dec 1;51(5):1299-304.

PMID:
11728690
8.

Phase I study of anti--epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer.

Robert F, Ezekiel MP, Spencer SA, Meredith RF, Bonner JA, Khazaeli MB, Saleh MN, Carey D, LoBuglio AF, Wheeler RH, Cooper MR, Waksal HW.

J Clin Oncol. 2001 Jul 1;19(13):3234-43.

PMID:
11432891
9.

NCCN Practice Guidelines for Head and Neck Cancers.

Pfister DG, Ang K, Brockstein B, Colevas AD, Ellenhorn J, Goepfert H, Hicks WL Jr, Hong WK, Kies MS, Lydiatt W, McCaffrey T, Mittal BB, Ridge JA, Schuller DE, Shah JP, Spencer S, Trotti A 3rd, Urba S, Weymuller EA Jr, Wheeler RH 3rd, Wolf GT; National Comprehensive Cancer Network.

Oncology (Williston Park). 2000 Nov;14(11A):163-94. No abstract available.

PMID:
11195409
10.

Combined modality therapy of A431 human epidermoid cancer using anti-EGFr antibody C225 and radiation.

Saleh MN, Raisch KP, Stackhouse MA, Grizzle WE, Bonner JA, Mayo MS, Kim HG, Meredith RF, Wheeler RH, Buchsbaum DJ.

Cancer Biother Radiopharm. 1999 Dec;14(6):451-63.

PMID:
10850332
11.

Evaluation of tamoxifen plus letrozole with assessment of pharmacokinetic interaction in postmenopausal women with metastatic breast cancer.

Ingle JN, Suman VJ, Johnson PA, Krook JE, Mailliard JA, Wheeler RH, Loprinzi CL, Perez EA, Jordan VC, Dowsett M.

Clin Cancer Res. 1999 Jul;5(7):1642-9.

12.

Monoclonal antibodies as potentiators of radiotherapy and chemotherapy in the management of head and neck cancer.

Wheeler RH, Spencer S, Buchsbaum D, Robert F.

Curr Opin Oncol. 1999 May;11(3):187-90. Review.

PMID:
10328593
13.

Concomitant chemotherapy and reirradiation as management for recurrent cancer of the head and neck.

Spencer SA, Wheeler RH, Peters GE, Beenken SW, Meredith RF, Smith J, Conner W, Salter MM.

Am J Clin Oncol. 1999 Feb;22(1):1-5.

PMID:
10025369
14.
15.

Correlation of toxicity with treatment parameters for 131I-CC49 radioimmunotherapy in three phase II clinical trials.

Liu T, Meredith RF, Saleh MN, Wheeler RH, Khazaeli MB, Plott WE, Schlom J, LoBuglio AF.

Cancer Biother Radiopharm. 1997 Apr;12(2):79-87.

PMID:
10851451
16.

High-performance liquid chromatographic determination of 9-(3-pyridylmethyl)-9-deazaguanine (BCX-34) in biological fluids.

Yan J, Lu Z, Walsh GM, Wheeler RH, Diasio RB.

J Chromatogr B Biomed Sci Appl. 1997 Mar 7;690(1-2):295-303.

PMID:
9106056
17.

Phase II study of dual 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer.

Meredith RF, Khazaeli MB, Plott WE, Grizzle WE, Liu T, Schlom J, Russell CD, Wheeler RH, LoBuglio AF.

Clin Cancer Res. 1996 Nov;2(11):1811-8.

18.

Prolonged infusion of etoposide in patients with advanced non-small cell lung cancer.

Robert F, Molthrop DC, Miller AA, Lee BC, Chen S, Wheeler RH.

Am J Clin Oncol. 1996 Oct;19(5):483-6.

PMID:
8823476
19.

Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49.

Meredith RF, Partridge EE, Alvarez RD, Khazaeli MB, Plott G, Russell CD, Wheeler RH, Liu T, Grizzle WE, Schlom J, LoBuglio AF.

J Nucl Med. 1996 Sep;37(9):1491-6.

20.

Phase I and pharmacologic study of 7- and 21-day continuous etoposide infusion in patients with advanced cancer.

Robert F, Chen S, Miller AA, Lee BC, Molthrop DC, Wheeler RH.

Cancer Chemother Pharmacol. 1996;38(5):459-65.

PMID:
8765440
21.

Initial clinical evaluation of iodine-125-labeled chimeric 17-1A for metastatic colon cancer.

Meredith RF, Khazaeli MB, Plott WE, Spencer SA, Wheeler RH, Brady LW, Woo DV, LoBuglio AF.

J Nucl Med. 1995 Dec;36(12):2229-33.

22.

Phase II trial of murine monoclonal antibody D612 combined with recombinant human monocyte colony-stimulating factor (rhM-CSF) in patients with metastatic gastrointestinal cancer.

Saleh MN, Khazaeli MB, Wheeler RH, Bucy RP, Liu T, Everson MP, Munn DH, Schlom J, LoBuglio AF.

Cancer Res. 1995 Oct 1;55(19):4339-46.

23.

Cisplatin plus radiation therapy.

Wheeler RH, Spencer S.

J Infus Chemother. 1995 Spring;5(2):61-6. Review.

PMID:
8521236
24.

Phase 2 study of prolonged administration of oral etoposide in combination with weekly cisplatin in advanced non-small cell lung cancer.

Robert F, Wheeler RH, Molthrop D, Bailey A, Chen S.

Am J Clin Oncol. 1994 Oct;17(5):383-6.

PMID:
8092106
25.

An efficient multiple-stage procedure for phase II clinical trials that have high response rate objectives.

Chen S, Soong SJ, Wheeler RH.

Control Clin Trials. 1994 Aug;15(4):277-83.

PMID:
7956267
26.

Tumor associated glycoprotein-72 is highly expressed in prostatic adenocarcinomas.

Myers RB, Meredith RF, Schlom J, LoBuglio AF, Bueschen AJ, Wheeler RH, Stockard CR, Grizzle WE.

J Urol. 1994 Jul;152(1):243-6.

PMID:
8201675
27.

Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49.

Meredith RF, Bueschen AJ, Khazaeli MB, Plott WE, Grizzle WE, Wheeler RH, Schlom J, Russell CD, Liu T, LoBuglio AF.

J Nucl Med. 1994 Jun;35(6):1017-22.

28.
29.

Evaluation of the methemoglobinemia associated with sulofenur.

Molthrop DC Jr, Wheeler RH, Hall KM, Prchal JT.

Invest New Drugs. 1994;12(2):99-102.

PMID:
7860238
30.

A phase I clinical trial of murine monoclonal antibody D612 in patients with metastatic gastrointestinal cancer.

Saleh MN, Khazaeli MB, Grizzle WE, Wheeler RH, Lawson S, Liu T, Russel C, Meredith R, Schlom J, LoBuglio AF.

Cancer Res. 1993 Oct 1;53(19):4555-62.

PMID:
8402627
31.

Direct localization comparison of murine and chimeric B72.3 antibodies in patients with colon cancer.

Meredith RF, Khazaeli MB, Grizzle WE, Orr RA, Plott G, Urist MM, Liu T, Russell CD, Wheeler RH, Schlom J, et al.

Hum Antibodies Hybridomas. 1993 Oct;4(4):190-7.

PMID:
8257773
32.

An in vivo and in vitro trial of aclarubicin in metastatic breast cancer: a novel approach to the study of analogs.

Natale RB, Cody RL, Simon MS, Wheeler RH.

Cancer Chemother Pharmacol. 1993;31(6):485-8.

33.
34.

Dose fractionation of radiolabeled antibodies in patients with metastatic colon cancer.

Meredith RF, Khazaeli MB, Liu T, Plott G, Wheeler RH, Russell C, Colcher D, Schlom J, Shochat D, LoBuglio AF.

J Nucl Med. 1992 Sep;33(9):1648-53.

35.

Phase I trial of the murine monoclonal anti-GD2 antibody 14G2a in metastatic melanoma.

Saleh MN, Khazaeli MB, Wheeler RH, Dropcho E, Liu T, Urist M, Miller DM, Lawson S, Dixon P, Russell CH, et al.

Cancer Res. 1992 Aug 15;52(16):4342-7.

36.

Phase I trial of the chimeric anti-GD2 monoclonal antibody ch14.18 in patients with malignant melanoma.

Saleh MN, Khazaeli MB, Wheeler RH, Allen L, Tilden AB, Grizzle W, Reisfeld RA, Yu AL, Gillies SD, LoBuglio AF.

Hum Antibodies Hybridomas. 1992 Jan;3(1):19-24.

PMID:
1576319
37.

Treatment of recurrent head and neck cancer with 5-fluorouracil, hydroxyurea, and reirradiation.

Weppelmann B, Wheeler RH, Peters GE, Kim RY, Spencer SA, Meredith RF, Salter MM.

Int J Radiat Oncol Biol Phys. 1992;22(5):1051-6.

PMID:
1555952
38.

Pharmacokinetics and immune response of 131I-chimeric mouse/human B72.3 (human gamma 4) monoclonal antibody in humans.

Khazaeli MB, Saleh MN, Liu TP, Meredith RF, Wheeler RH, Baker TS, King D, Secher D, Allen L, Rogers K, et al.

Cancer Res. 1991 Oct 15;51(20):5461-6.

39.

Multicenter clinical trial of mitoxantrone in non-Hodgkin's lymphoma and Hodgkin's disease.

Silver RT, Case DC Jr, Wheeler RH, Miller TP, Stein RS, Stuart JJ, Peterson BA, Rivkin SE, Golomb HM, Costanzi, et al.

J Clin Oncol. 1991 May;9(5):754-61.

PMID:
2016617
40.

In-111 labeled monoclonal anti-carcinoembryonic antigen antibody (ZCE025) in the immunoscintigraphic imaging of metastatic antigen-producing adenocarcinomas.

Saleh MN, Wheeler RH, Lee JY, Khazaeli MB, Unger MW, Russell CH, LoBuglio AF.

Clin Nucl Med. 1991 Feb;16(2):110-6.

PMID:
2004491
41.

A phase I study of prolonged infusion 5-fluorouracil and concomitant radiation therapy in patients with squamous cell cancer of the head and neck.

Weppelmann B, Wheeler RH, Peters GE, Stephens S, Spencer SA, Meredith RF, Kim RY, Salter MM.

Int J Radiat Oncol Biol Phys. 1991 Feb;20(2):357-60.

PMID:
1991701
43.

Pharmacokinetics of a mouse/human chimeric monoclonal antibody (C-17-1A) in metastatic adenocarcinoma patients.

Trang JM, LoBuglio AF, Wheeler RH, Harvey EB, Sun L, Ghrayeb J, Khazaeli MB.

Pharm Res. 1990 Jun;7(6):587-92.

PMID:
2367327
44.

A phase II trial of murine monoclonal antibody 17-1A and interferon-gamma: clinical and immunological data.

Saleh MN, LoBuglio AF, Wheeler RH, Rogers KJ, Haynes A, Lee JY, Khazaeli MB.

Cancer Immunol Immunother. 1990;32(3):185-90.

PMID:
2126988
45.

Chemotherapy of patients with recurrent head and neck cancer.

Wheeler RH.

Cancer Treat Res. 1990;52:171-93. Review. No abstract available.

PMID:
1976365
46.

Mouse/human chimeric monoclonal antibody in man: kinetics and immune response.

LoBuglio AF, Wheeler RH, Trang J, Haynes A, Rogers K, Harvey EB, Sun L, Ghrayeb J, Khazaeli MB.

Proc Natl Acad Sci U S A. 1989 Jun;86(11):4220-4.

47.

Cisplatin and mitoguazone. An induction chemotherapy regimen in advanced head and neck cancer.

Forastiere AA, Perry DJ, Wolf GT, Wheeler RH, Natale RB.

Cancer. 1988 Dec 1;62(11):2304-8.

PMID:
3179946
49.

Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. II. Pharmacokinetics and immune response.

Khazaeli MB, Saleh MN, Wheeler RH, Huster WJ, Holden H, Carrano R, LoBuglio AF.

J Natl Cancer Inst. 1988 Aug 17;80(12):937-42.

PMID:
3398069
50.

Phase I trial of multiple large doses of murine monoclonal antibody CO17-1A. I. Clinical aspects.

LoBuglio AF, Saleh MN, Lee J, Khazaeli MB, Carrano R, Holden H, Wheeler RH.

J Natl Cancer Inst. 1988 Aug 17;80(12):932-6.

PMID:
3398068

Supplemental Content

Loading ...
Support Center